Chimerix

2006

Chimerix Announced Initiation of Phase I clinical trials of CMX001, An Oral Treatment for Smallpox Infection    

RESEARCH TRIANGLE PARK, NC, June 28 2006 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that it has received U.S. Food and Drug Administration clearance for its Investigational New Drug… > Read More

Chimerix Acquires Lead Compound Library of Antiviral Agents from University of Michigan    

RESEARCH TRIANGLE PARK, NC, May 24 2006 - Chimerix, Inc., an emerging biotechnology company developing orally available antiviral therapeutics, announced today that it has acquired Dr. Leroy Townsend’s lifetime library of chemical lead compounds from the University… > Read More

Chimerix and USAMRIID Collaborate to Complete Preclinical Development of Smallpox Therapeutic    

RESEARCH TRIANGLE PARK, NC, April 18, 2006 - Chimerix, Inc., a biotechnology company developing orally available, targeted medicines to treat smallpox and other viral infections, announced today that it has signed a Cooperative Research and Development Agreement (CRADA)… > Read More